Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Panel Supports Ono’s Cancer Drug Carfilzomib
April 26, 2016
- 13 New Countries Join Japan-EU Mutual Acceptance Scheme for GMP Data
April 26, 2016
- PMDA Reviewing Risk of Hep B Virus Reactivation for Sovaldi, Harvoni, Other Hep C Drugs
April 26, 2016
- PMDA Now Has 560 Full-Time Employees in Review Division
April 25, 2016
- Making PMDA World’s Most Trusted Regulatory Authority through “Regulatory Innovation”: Chief Executive
April 25, 2016
- Panel Eyes FY2017 Discussion Deadline for Prescribing Rules for Lifestyle Disease Drugs
April 22, 2016
- Giotrif Label to Add Acute Pancreatitis as Clinically Significant ADR
April 22, 2016
- Boehringer’s Triple Combo Hypertension Drug Put on Hold by MHLW Advisory Panel
April 21, 2016
- Key Govt Panel Launches Discussions on New Growth Strategy
April 20, 2016
- Opdivo’s Fulminant Type 1 Diabetes Risk Re-Stressed in MHLW Safety Bulletin
April 20, 2016
- LDP Finalizes Proposal for Growth Strategy; Touches on CIN, Drug Discovery Seeds
April 20, 2016
- Sales Reps Top Source of Drug Safety Information for Both Clinics and Pharmacies: PMDA Survey
April 19, 2016
- Wholesalers Cited Urgent Deliveries as Major Concern: Ryukaikon
April 19, 2016
- Wholesalers’ Negative Primary Margins on Sales Level Off: Ryukaikon
April 18, 2016
- PMDA Had 58 Paid Advisory Sessions on Drug Development for Startups, Academia: FY2015
April 18, 2016
- Ryukaikon Agrees on Mandatory Barcode Labeling by March 2021; March 2022 for Exceptions
April 18, 2016
- Quake Brings Production Offline at 1 Out of 24 Firms in Affected Region: MHLW
April 18, 2016
- Promoting Use of Patient Registries Important in Building Clinical Innovation Network: Health Policy Bureau Chief
April 18, 2016
- Dyslipidemia Risk Triples in Patients on Olanzapine: PMDA Epidemiology Study
April 15, 2016
- Expedited Review Systems Now in Place in 3 Major Markets, but How Are They Different?
April 15, 2016
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…